interferon alfa-2b


Bio Sidus


BJC Healthcare
Concise Prescribing Info
Recombinant human interferon α-2b
Dosage/Direction for Use
Chronic hepatitis B 30-35 MIU/wk SC/IM as 5 MIU/day or 10 MIU 3 times/wk for 16-24 wk. Childn 1-17 yr 3 MIU/m2 3 times/wk (every other day) for the 1st wk of therapy. Increase to 6 MIU/m2 3 times/wk SC. Max: 10 MIU 3 times/wk. Total therapy duration: 16-24 wk. Chronic hepatitis C 3 MIU SC 3 times/wk for up to 18-24 mth. Resp tract papillomatosis eg, laryngeal papillomatosis 3 MIU/m2 SC 3 times/wk after surgical (laser) removal of tumor tissue. Condylomata acuminatum 1 MIU injected into lesion 3 times/wk on alternate days for 3 wk. Max: ≤15 MIU/wk. Malignant melanoma Adjuvant to surgery: 20 MIU/m2 IV 5 times wkly for 4 wk, followed by 10 MIU/m2 SC 3 times wkly for 48 wk. In combination w/ chemotherapy 15 MIU/m2 IV 5 times wkly for 3 wk, followed by 10 MIU/m2 SC 3 times wkly. AIDS-Related Kaposi's sarcoma 30 MIU/m2 SC/IM 3-5 times/wk or 50 MIU/m2/day as 30 min IV infusion for 5 consecutive days followed by a min interval of 9 days until the next 5-day treatment period. Concomitant administration w/ zidovudine (AZT) 5-10 MIU/m2/day; AZT 100 mg every 4 hr. Renal cell carcinoma Monotherapy: 3-30 MIU SC 3, 5 or 7 days/wk. Combination therapy: 3-20 MIU/m2 SC. Hairy cell leukemia 2 MIU/m2 SC/IM 3 times/wk. Non-Hodgkin's lymphoma 5 MIU SC 3 times/wk. Cutaneous T-Cell lymphoma 1-2 MIU/inj site 3 times/wk for 4 consecutive wk. Multiple myeloma Induction therapy: 3-5 MIU/m2 3 times/wk. Maintenance: SC 3-5 MIU/m2 3 times/wk.
Hypersensitivity. Pregnancy & lactation.
Special Precautions
Monitor patients receiving interferon for long periods & in high dose: WBC & platelet count, hepatic enzymes (TGO & TGP), urea, creatinine. Patients w/ history of cardiac abnormalities should be monitored by ECG. May impair ability to drive or operate machinery. Ensure adequate hydration.
Adverse Reactions
Pain & erythema at site of inj. Systemic: Fever, flu-like syndrome, headache, hyperthermia, myalgia; anorexia, asthenia, nausea, diarrhea, diminished number of circulating leukocytes & platelets.
MIMS Class
Antivirals / Cancer Immunotherapy
ATC Classification
L03AB05 - interferon alfa-2b ; Belongs to the class of interferons. Used as immunostimulants.
Bioferon inj 3 MIU
Bioferon inj 5 MIU
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in